{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.16","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"21"},{"groupId":"OG001","spread":"25","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Percent change of NF-kB =\\[(expression at 4 weeks- expression at baseline)/expression at baseline\\]\\*100%. Bone marrow aspirate/biopsy for expression of NF-kB and related genes/proteins markers at baseline and after 4 weeks.","dispersionType":"Standard Deviation","groups":[{"description":"Curcumin starting dose 2 grams orally in two divided doses (a.m., p.m.)","id":"OG000","title":"Curcumin"},{"description":"Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily","id":"OG001","title":"Curcumin + Bioperine"}],"paramType":"MEAN","populationDescription":"All participants in the two arms (Curcumin versus Curcumin plus Bioperine) who received at least 4 weeks of treatment were eligible for outcome evaluation.","reportingStatus":"POSTED","timeFrame":"Baseline through 4 weeks of treatment","title":"Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment","type":"PRIMARY","unitOfMeasure":"Percent reduction"}